ORYZON receives approval from AEMPS to start SATEEN: a Phase IIA clinical trial in Multiple Sclerosis with ORY-2001

31 October 2017 MADRID, SPAIN and CAMBRIDGE MA. • The company expects to start enrollment before year’s end Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced that it has received approval of a Clinical Trial Application (CTA), the European IND equivalent, from the Spanish Drug Agency (AEMPS) to conduct a PhaseIIA clinical study with ORY-2001 in patients of Multiple Sclerosis (MS). Click here to see the full Press Release

The release as fetched from its publisher. oryzon.com ↗